Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gridelli, C, Frontini, L, Perrone, F, Gallo, C, Gulisano, M, Cigolari, S, Castiglione, F, Robbiati, S F, Gasparini, G, Ianniello, G P, Farris, A, Locatelli, M C, Felletti, R, Piazza, E
Natura: Articolo
Lingua:English
Pubblicazione: Nature Publishing Group 2000
Soggetti:
Regular Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Accesso online

https://ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://ncbi.nlm.nih.gov/pubmed/10952772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2000.1341

Documenti analoghi